Delivery of rizatriptan or zolmitriptan through an inhalation route
View Patent ↗The present invention relates to the delivery of compounds for the treatment of migraine and headache through an inhalation route. Specifically, it relates to aerosols containing rizatriptan or zolmitriptan that are used in inhalation therapy. In a method aspect of the present invention, rizatriptan or zolmitriptan is administered to a patient through an inhalation route. The method comprises: a) heating a thin layer of rizatriptan or zolmitriptan on a solid support to form a vapor; and, b) passing air through the heated vapor to produce aerosol particles having less than 5% drug degradation products. In a kit aspect of the present invention, a kit for delivering rizatriptan or zolmitriptan through an inhalation route is provided which comprises: a) a thin coating of a rizatriptan or zolmitriptan composition; and, b) a device for dispending said thin coating as a condensation aerosol.
1. A dose form of rizatriptan comprising a condensation aerosol
formed by heating a thin layer containing rizatriptan, on a solid support, to produce a vapor of rizatriptan and condensing the vapor to form a condensation aerosol characterized by less than 10% rizatriptan degradation products by weight, and
an MMAD of less than 5 microns, wherein the dose form comprises less than 4 mg of rizatriptan.
2. A dose form of zolmitriptan comprising a condensation aerosol
formed by heating a thin layer containing zolmitriptan, on a solid support, to produce a vapor of zolmitriptan and condensing the vapor to form a condensation aerosol characterized by less than 10% zolmitriptan degradation products by weight, and
an MMAD of less than 5 microns, wherein the dose form comprises less than 1 mg zolmitriptan.
3. A method of producing a dose form of rizatriptan comprising a condensation aerosol, the method comprising:
a. heating a thin layer containing rizatriptan, on a solid support, to produce a vapor of rizatriptan, and
b. providing an air flow through the vapor to form a condensation aerosol characterized by less than 10% rizatriptan degradation products by weight, and an MMAD of less than 5 microns, wherein the dose form comprises less than 4 mg of rizatriptan.
4. A method of producing a dose form of zolmitriptan comprising a condensation aerosol, the method comprising:
a. heating a thin layer containing zolmitriptan on a solid support, to produce a vapor of zolmitriptan, and
b. providing an air flow through the vapor to form a condensation aerosol characterized by less than 10% zolmitriptan degradation products by weight, and an MMAD of less than 5 microns, wherein the dose form comprises less than 1 mg of zolmitriptan.
5. A condensation aerosol for delivery of rizatriptan, wherein the condensation aerosol is formed by heating a thin layer containing rizatriptan, on a solid support, to produce a vapor of rizatriptan and condensing the vapor to form a condensation aerosol characterized by less than 5% rizatriptan N-oxide or didehydro rizatriptan by weight, and an MMAD of less than 5 microns.
6. A condensation aerosol for delivery of zolmitriptan, wherein the condensation aerosol is formed by heating a thin layer containing zolmitriptan, on a solid support, to produce a vapor of zolmitriptan and condensing the vapor to form a condensation aerosol characterized by less than 5% zolmitriptan N-oxide or didehydro zolmitriptan by weight, and an MMAD of less than 5 microns.
7. A method of producing rizatriptan in an aerosol form comprising:
a. heating a thin layer containing rizatriptan, on a solid support, to produce a vapor of rizatriptan, and
b. providing an air flow thorough the vapor to form a condensation aerosol characterized by less than 5% rizatriptan N-oxide or didehydro rizatriptan by weight, and an MMAD of less than 5 microns.
8. A method of producing zolmitriptan in an aerosol form comprising:
a. heating a thin layer containing zolmitriptan, on a solid support, to produce a vapor of zolmitriptan, and
b. providing an air flow thorough the vapor to form a condensation aerosol characterized by less than 5% zolmitriptan N-oxide or didehydro zolmitriptan by weight, and an MMAD of less than 5 microns.